Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials.
Gogas BD, Bourantas CV, Garcia-Garcia HM, Onuma Y, Muramatsu T, Farooq V, Diletti R, van Geuns RJ, De Bruyne B, Chevalier B, Thuesen L, Smits PC, Dudek D, Koolen J, Windecker S, Whitbourn R, McClean D, Dorange C, Miquel-Hebert K, Veldhof S, Rapoza R, Ormiston JA, Serruys PW. Gogas BD, et al. Among authors: ormiston ja. EuroIntervention. 2013 Oct;9(6):709-20. doi: 10.4244/EIJV9I6A115. EuroIntervention. 2013. PMID: 23628499 Free article.
Bioresorbable scaffold technologies.
Onuma Y, Ormiston J, Serruys PW. Onuma Y, et al. Circ J. 2011;75(3):509-20. doi: 10.1253/circj.cj-10-1135. Epub 2011 Feb 3. Circ J. 2011. PMID: 21301138 Free article. Review.
Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?
Brugaletta S, Radu MD, Garcia-Garcia HM, Heo JH, Farooq V, Girasis C, van Geuns RJ, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Rapoza R, Miquel-Hebert K, Ormiston J, Serruys PW. Brugaletta S, et al. Atherosclerosis. 2012 Mar;221(1):106-12. doi: 10.1016/j.atherosclerosis.2011.12.008. Epub 2011 Dec 13. Atherosclerosis. 2012. PMID: 22209268 Clinical Trial.
Differences in neointimal thickness between the adluminal and the abluminal sides of malapposed and side-branch struts in a polylactide bioresorbable scaffold: evidence in vivo about the abluminal healing process.
Gutiérrez-Chico JL, Gijsen F, Regar E, Wentzel J, de Bruyne B, Thuesen L, Ormiston J, McClean DR, Windecker S, Chevalier B, Dudek D, Whitbourn R, Brugaletta S, Onuma Y, Serruys PW. Gutiérrez-Chico JL, et al. JACC Cardiovasc Interv. 2012 Apr;5(4):428-35. doi: 10.1016/j.jcin.2011.12.015. JACC Cardiovasc Interv. 2012. PMID: 22516401 Free article.
Vascular compliance changes of the coronary vessel wall after bioresorbable vascular scaffold implantation in the treated and adjacent segments.
Brugaletta S, Gogas BD, Garcia-Garcia HM, Farooq V, Girasis C, Heo JH, van Geuns RJ, de Bruyne B, Dudek D, Koolen J, Smits P, Veldhof S, Rapoza R, Onuma Y, Ormiston J, Serruys PW. Brugaletta S, et al. Circ J. 2012;76(7):1616-23. doi: 10.1253/circj.cj-11-1416. Epub 2012 Apr 24. Circ J. 2012. PMID: 22531596 Free article. Clinical Trial.
Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device: the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Nieman K, Serruys PW, Onuma Y, van Geuns RJ, Garcia-Garcia HM, de Bruyne B, Thuesen L, Smits PC, Koolen JJ, McClean D, Chevalier B, Meredith I, Ormiston J. Nieman K, et al. J Am Coll Cardiol. 2013 Nov 5;62(19):1813-4. doi: 10.1016/j.jacc.2013.07.030. Epub 2013 Aug 7. J Am Coll Cardiol. 2013. PMID: 23933536 Free article. No abstract available.
Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial.
Bourantas CV, Farooq V, Zhang Y, Muramatsu T, Gogas BD, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Dorange C, Rapoza R, Onuma Y, Garcia-Garcia HM, Serruys PW. Bourantas CV, et al. EuroIntervention. 2015 Mar;10(11):1299-306. doi: 10.4244/EIJY14M04_11. EuroIntervention. 2015. PMID: 24769420 Free article.
Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data.
Bourantas CV, Serruys PW, Nakatani S, Zhang YJ, Farooq V, Diletti R, Ligthart J, Sheehy A, van Geuns RJ, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Rapoza R, Veldhof S, Onuma Y, Garcia-Garcia HM. Bourantas CV, et al. EuroIntervention. 2015 Nov;11(7):746-56. doi: 10.4244/EIJY14M10_06. EuroIntervention. 2015. PMID: 25308301 Free article.
DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial.
Iqbal J, Verheye S, Abizaid A, Ormiston J, de Vries T, Morrison L, Toyloy S, Fitzgerald P, Windecker S, Serruys PW. Iqbal J, et al. EuroIntervention. 2016 Dec 10;12(11):e1336-e1342. doi: 10.4244/EIJY15M10_04. EuroIntervention. 2016. PMID: 26465374 Free article. Clinical Trial.
A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.
Serruys PW, Ormiston J, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Chevalier B, Smits P, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Wasungu L, Ediebah D, Veldhof S, Onuma Y. Serruys PW, et al. J Am Coll Cardiol. 2016 Feb 23;67(7):766-76. doi: 10.1016/j.jacc.2015.11.060. J Am Coll Cardiol. 2016. PMID: 26892411 Free article. Clinical Trial.
249 results